大洋生物(003017) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥233,074,330.13, a decrease of 3.90% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥16,318,921.47, an increase of 27.90% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,747,048.54, a slight decrease of 0.12% compared to the previous year[5]. - Basic and diluted earnings per share for Q3 2023 were both ¥0.27, representing an increase of 28.57% year-on-year[5]. - Total operating revenue for Q3 2023 was CNY 714,741,924.74, a decrease of 2.9% compared to CNY 735,173,544.19 in the same period last year[22]. - Operating profit for Q3 2023 was CNY 39,880,452.30, a decline of 11.5% compared to CNY 44,840,892.05 in Q3 2022[22]. - Net profit for the period was CNY 38,817,190.88, down from CNY 43,931,123.28 in the previous year[22]. - The net profit for Q3 2023 is ¥40,176,231.69, a decrease of 19.3% compared to ¥50,100,877.55 in Q3 2022[23]. - Basic and diluted earnings per share for Q3 2023 are both ¥0.68, down from ¥0.84 in the same period last year, representing a decline of 19.0%[23]. Assets and Liabilities - Total assets at the end of Q3 2023 reached ¥1,591,431,883.53, an increase of 5.53% from the end of the previous year[5]. - Total assets reached CNY 1,591,431,883.53, up from CNY 1,507,973,920.76 at the start of the year[20]. - Total liabilities increased to CNY 590,101,277.39, compared to CNY 522,924,492.77 at the beginning of the year[20]. - Long-term equity investments increased by 610.25% to ¥17,762,640.62, primarily due to additional investments in joint ventures[9]. - The company reported a 34.11% decrease in prepaid expenses, attributed to a reduction in inventory due to falling raw material prices[9]. - Contract liabilities decreased by 42.76% to ¥4,596,833.81, mainly due to a reduction in advance receipts at the end of the period[9]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥70,707,053.73, an increase of 16.20%[5]. - Cash inflow from operating activities totaled ¥636,437,817.31, a decrease of 10.0% from ¥707,227,132.03 in Q3 2022[26]. - The net cash flow from operating activities increased to ¥70,707,053.73, up by 16.8% compared to ¥60,849,462.15 in the previous year[26]. - Cash flow from investing activities generated a net inflow of ¥212,321,952.98, a significant improvement from a net outflow of ¥119,529,791.00 in Q3 2022[26]. - The company reported cash inflow from financing activities of ¥407,744,680.85, down from ¥548,529,139.25 in the same quarter last year[27]. - Total cash outflow from financing activities decreased to ¥355,337,786.30, compared to ¥579,591,880.94 in Q3 2022[27]. - The net increase in cash and cash equivalents was ¥335,730,188.69, a substantial recovery from a decrease of ¥87,936,336.69 in the previous period[11]. - Cash and cash equivalents increased to CNY 468,492,052.31 as of September 30, 2023, compared to CNY 131,111,370.93 at the beginning of the year[19]. - Cash and cash equivalents at the end of Q3 2023 reached ¥466,841,559.62, compared to ¥43,947,026.44 at the end of Q3 2022, indicating a substantial increase[27]. Expenses and Investments - Total operating costs for Q3 2023 were CNY 689,420,155.68, down 2.4% from CNY 706,453,483.97 year-over-year[22]. - Employee compensation decreased by 30.83% to ¥9,591,918.47 due to the distribution of 2022 year-end bonuses in the previous period[10]. - Tax payable decreased by 78.67% to ¥3,199,693.59, primarily due to a reduction in the value-added tax balance compared to the beginning of the period[10]. - Other payables increased by 75.09% to ¥55,014,101.97, mainly due to an increase in dividends payable at the end of the reporting period[10]. - Long-term borrowings increased by 100% to ¥69,000,000.00, attributed to new long-term working capital loans during the reporting period[10]. - Research and development expenses for the period were CNY 30,959,515.47, an increase from CNY 26,378,606.21 in the previous year[22]. - Management expenses rose by 32.18% to ¥51,138,022.60, mainly due to an increase in share-based payment amounts compared to the same period last year[10]. - Asset impairment losses increased by 914.15% to ¥-2,265,735.11, primarily due to higher provisions for inventory depreciation compared to the previous year[10]. Corporate Actions - The company completed the first unlocking period of the 2022 employee stock ownership plan, unlocking 1.12 million shares, accounting for 1.87% of the total share capital[15]. - The company plans to increase capital for its wholly-owned subsidiary, Fujian Shunyu Technology Co., Ltd., using remaining raised funds for the "Trifluoroacetyl Series Products Project"[17]. - The report indicates that the company has not made any acquisitions or significant new product announcements during this period[28]. - The company has not undergone an audit for the Q3 2023 report[28].